Advance Technologies

先进技术核心（ATC）的主要功能是支持GNL研究人员， 将基础科学知识和发现转化为改善人类健康的实际措施。 在GNL进行的研究将为治疗和诊断确定许多新的潜在靶点 对抗威胁生命的传染病。在履行其中心职能时，ATC将提供的第一项服务是 将提供资源和专业知识，以开发利用这些新靶点的体外测定法， 技术，从研究工作台到标准化，可重复和验证的格式， 可用于中高通量筛选（HTS）研究。只要有可能，ATC将 重点是开发可在低浓度BSL 2条件下进行的试验， 最大限度地提高其随后对研究界的效用。然而，并不是所有开发的测定都将是有效的。 适用于BSL 2使用，许多BSL 2检测的有效验证将需要确证性研究 在BSL 3或BSL 4控制下使用活病原体。因此，作为其体外试验开发的一部分， 功能，核心不仅将保持BSL 2遏制资源，而且将有资源进行 在BSL 3和BSL 4密闭条件下的试验开发。 空中交通管制将为GNL提供的第二项服务将是利用 其开发的检测试剂盒，或在BSL 2和BSL 3控制下的其他现有检测试剂盒， 在BSL 4控制下进行小规模研究的额外能力。该筛选程序将 为GNL研究人员提供鉴定活性化合物的能力，以作为开发 潜在的新疗法 ATC的第三个主要服务将是协调GNL研究人员与 资源和专业知识的专门研究核心，已经存在于UTMB校园。在这个角色中 空中交通管制将从两个不同的方面直接促进GNL的成本效益运行。首先，它将 确保GNL研究人员充分利用现有资源，而不是重复使用， 其次，它将最大限度地减少单个研究人员访问这些资源所需的时间和精力， 通过充当单个源接入点来实现临时基础。这将直接提高研究效率 为了GNL。

The central function of the Advanced Technologies core (ATC) will be to support GNL researchers in translating basic science knowledge and discoveries into practical measures to improve human health. Research undertaken in the GNL will identify many new potential targets for therapeutics and diagnostics against life threatening infectious diseases. In fulfilling its central function the first service that the ATC will provide will be the resources and expertise to develop in vitro assays that utilize such new targets and technologies, from the research bench top to a standardized, reproducible and validated format suitable that can be used in medium to high throughput screening (HTS) studies. Wherever possible the ATC will place emphasis on developing assays that can be conducted under low containment BSL2 conditions which will maximize their subsequent utility to the research community. However, not all assays developed will be suitable for BSL2 use and, effective validation of many of the BSL2 assays will require confirmatory studies using live pathogens under BSL3 or BSL4 containment. Therefore, as part of its in vitro assay development function the core will not only maintain BSL2 containment resources but will have the resources to conduct assay development under BSL3 and BSL4 containment conditions. The second service that the ATC will provide to the GNL will be infrastructure to conduct HTS studies using the assays that it develops, or other already existing assays under both BSL2 and BSL3 containment with the additional capacity to conduct small scale studies under BSL4 containment. This screening program will provide GNL researchers with the ability to identify active compounds to serve as leads for development of potential new therapeutics. The third major service of the ATC will be to coordinate interactions between GNL researchers and those resources and expertise in specialized research cores that already exist on the UTMB campus. In this role the ATC will contribute directly to the cost effective running of the GNL in two distinct ways. Firstly, it will ensure that GNL researchers make full use of existing resources rather than duplicating them and, secondly, it will minimize the time and effort involved in individual researchers accessing these resources on an ad hoc basis by acting as a single source point of access. This will directly increase research efficiency for the GNL.